The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial
Abstract
BACKGROUND: Unlike antiarrhythmic drugs, the safety and beneficial effects of angiotensin II receptor blockade (ARB) in patients with structural heart disease is well established. The clinical efficacy of ARBs to prevent atrial fibrillation (AF) so far only has been shown in patients with structural heart disease. Here, we report the primary outcome of the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) trial, which investigated the effect of olmesartan medoxomil compared with placebo on AF burden in patients with paroxysmal AF without structural heart disease. METHODS AND RESULTS: The ANTIPAF trial was a prospective, randomized, placebo-controlled, multicenter trial analyzing the AF burden (percentage of days with documented episodes of paroxysmal AF) during a 12-month follow-up as the primary study end point. Four hundred thirty patients with documented paroxysmal AF without structural heart disease were randomized to placebo or 40 mg olmesartan per day. Concomitant therapy with ARBs, angiotensin-converting enzyme inhibitors, and antiarrhythmic drugs was prohibited. Patients were followed using daily transtelephonic ECG (tele-ECG) recordings independent of symptoms. The intention-to-treat population of the trial encompassed 425 patients (placebo group, n=211; olmesartan group, n=214). A total of 87 818 tele-ECGs were analyzed in these patients during follow-up (placebo group, 44 888 ECGs; olmesartan group, 42 930 ECGs). Thus, a mean of 207 tele-ECGs were recorded per patient. The primary end point (AF burden) was not different between the 2 groups (P=0.770). Secondary outcome parameters, including quality of life, also were not different. In particular, time to first AF recurrence, time to persistent AF, and number of hospitalizations were not different between the 2 groups. The time to prescription of recovery medication (amiodarone) was the only parameter showing an intergroup difference, with earlier prescription of amiodarone in the placebo group (P=0.022). CONCLUSIONS: One year of ARB therapy per se does not reduce the number of AF episodes in patients with documented paroxysmal AF without structural heart disease. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00098137.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The reduced incidence of AF with ACE inhibitors/ARBs is less evident in patients with HFpEF 239 and is lost in patients without heart failure.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [241]
In the citing paper
“In patients with established AF, but without LV dysfunction or heart failure, ARBs do not prevent recurrent AF better than placebo.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [241]
In the citing paper
“ARB therapy did not reduce the AF burden in patients with AF without structural heart disease.241”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [241]
In the citing paper
“Similarly, polyunsaturated fatty acids failed to show convincing benefit.241,[694][695][696][697][698]”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [241]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001) · JAMA · doi:10.1001/jama.285.18.2370 · Cited by 6,205
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,954
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Epidemiologic Features of Chronic Atrial Fibrillation
Kannel, W. B., Abbott, R. D., Savage, D. D., & McNamara, P. M. (1982) · New England Journal of Medicine · doi:10.1056/nejm198204293061703 · Cited by 2,304
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · EP Europace · doi:10.1093/europace/euq350 · Cited by 1,764
New ideas about atrial fibrillation 50 years on
Nattel, S. (2002) · Nature · doi:10.1038/415219a · Cited by 1,481
Promotion of Atrial Fibrillation by Heart Failure in Dogs
Li, D., Fareh, S., Leung, T. K., & Nattel, S. (1999) · Circulation · doi:10.1161/01.cir.100.1.87 · Cited by 1,343
The AFFIRM Investigators (2004) · Circulation · doi:10.1161/01.cir.0000121736.16643.11 · Cited by 1,202
Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826
Research works printed but not linked: 1
- Maurer W, Hothorn LA, Lehmacher W Multiple comparisons in drug clinical trials and preclinical assays: a priori ordered hypotheses. In: , Vollmar J , ed. Biometrie in der Chemisch-Pharmazeutischen Industrie, Band 6. Stuttgart, Germany: Fischer; 1995: 13–18.
Cited by
Sorted by citations
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,739
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castella, M., Dan, G.-A., Dilaveris, P., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa612 · Cited by 10,550
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,823
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.022 · Cited by 2,955
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,929
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A. M., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 3,145
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000040 · Cited by 2,056
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.017 · Cited by 933
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension
Mancia, G., Fagard, R. H., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T. C., Cífková, R., Backer, G. D., Dominiczak, A. F., et al. (2013) · Blood Pressure · doi:10.3109/08037051.2014.868629 · Cited by 749
Daskalopoulou, S. S., Rabi, D. M., Zarnke, K. B., Dasgupta, K., Nerenberg, K. A., Cloutier, L., Gelfer, M., Lamarre-Cliché, M., Milot, A., Bolli, P., et al. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.02.016 · Cited by 690
“ARBs have not prevented recurrences of paroxysmal or persistent atrial fibrillation [CAndesartan in the Prevention of Relapsing Atrial Fibrillation (CAPRAF) [573], Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Atrial Fibrillation (GISSI-AF) [574], and ANgioTensin II Antagonist In Paroxysmal…”
BackgroundJanuary, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.021 · Cited by 581
2013 ESH/ESC Guidelines for the management of arterial hypertension
Mancia, G., Fagard, R. H., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T. C., Cífková, R., Backer, G. D., Dominiczak, A. F., et al. (2013) · Blood Pressure · doi:10.3109/08037051.2013.812549 · Cited by 430
“ARBs have not prevented recurrences of paroxysmal or persistent atrial fibrillation [CAndesartan in the Prevention of Relapsing Atrial Fibrillation (CAPRAF) [573], Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico-Atrial Fibrillation (GISSI-AF) [574], and ANgioTensin II Antagonist In Paroxysmal…”
BackgroundEpidemiology and modifiable risk factors for atrial fibrillation
Elliott, A. D., Middeldorp, M. E., Gelder, I. C. V., Albert, C. M., & Sanders, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00820-8 · Cited by 392
Goette, A., Corradi, D., Dobrev, D., Aguinaga, L., Cabrera, J. Á., Chugh, S. S., de Groot, J. R., Soulat-Dufour, L., Fenelon, G., Hatem, S. N., et al. (2024) · EP Europace · doi:10.1093/europace/euae204 · Cited by 370
Daskalopoulou, S. S., Khan, N. A., Quinn, R. R., Ruzicka, M., McKay, D. W., Hackam, D. G., Rabkin, S. W., Rabi, D. M., Gilbert, R. E., Padwal, R. S., et al. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.02.018 · Cited by 264
Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation
Kirchhof, P. F., Hæusler, K. G., Blank, B., de Bono, J. P., Callans, D. J., Elvan, A., Fetsch, T., Gelder, I. C. V., Gentlesk, P. J., Grimaldi, M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy176 · Cited by 240
2020 Clinical guidelines for Atrial fibrillation and atrial flutter
Arakelyan, M. S., Bockeria, L. A., Vasilieva, E., Sp, G., Golukhova, E. Z., Gorev, M. V., Davtyan, K. V., Drapkina, O. M., Станиславовна, К. Е., Kuchinskaya, Е. А., et al. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2021-4594 · Cited by 258
Clinical Classifications of Atrial Fibrillation Poorly Reflect Its Temporal Persistence
Charitos, E. I., Pürerfellner, H., Glotzer, T. V., & Ziegler, P. D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.019 · Cited by 188
The future of atrial fibrillation management: integrated care and stratified therapy
Kirchhof, P. F. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31072-3 · Cited by 182
Catheter ablation in patients with persistent atrial fibrillation
Kirchhof, P. F., & Calkins, H. G. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw260 · Cited by 156
Risk Factor Management in Atrial Fibrillation
Brandes, A., Smit, M. D., Nguyen, B. O., Rienstra, M., & Gelder, I. C. V. (2018) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2018.18.2 · Cited by 163
Atrial fibrillation burden: a new outcome predictor and therapeutic target
Becher, N., Metzner, A., Toennis, T., Kirchhof, P. F., & Schnabel, R. B. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae373 · Cited by 169
“25 The daily AF burden in RACE-V increased from 3.2% to 3.8%, 5.2%, and 6.1% in patients with paroxysmal AF undergoing continuous rhythm monitoring by implanted devices.”
BackgroundInfluentialRole of Inflammation in the Pathogenesis of Atrial Fibrillation
Ihara, K., & Sasano, T. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.862164 · Cited by 146
Fabritz, L., Guasch, E., Antoniades, C. A., Bardinet, I., Benninger, G., Betts, T. R., Brand, E., BREITHARDT, G. E., Suchánková, G., Camm, A. J., et al. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.194 · Cited by 144
Chiang, C., Wu, T.-J., Ueng, K.-C., Chao, T., Chang, K., Wang, C.-C., Lin, Y., Yin, W., Kuo, J., Lin, W., et al. (2016) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.10.005 · Cited by 138
Menezes, A. R., Lavie, C. J., DiNicolantonio, J. J., O’Keefe, J. H., Morin, D. P., Khatib, S., & Milani, R. V. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.022 · Cited by 141
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-20-1212 · Cited by 132
Görenek, B., Pelliccia, A., Benjamin, E. J., Boriani, G., Crijns, H. J. G. M., Fogel, R. I., Gelder, I. C. V., Halle, M., Kudaiberdieva, G., Lane, D. A., et al. (2016) · EP Europace · doi:10.1093/europace/euw242 · Cited by 134
Atrial fibrillation and stroke
Choi, S. E., Sagris, D., Hill, A. M., Lip, G. Y. H., & Abdul‐Rahim, A. H. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2160319 · Cited by 142
Implications of Inflammation and Fibrosis in Atrial Fibrillation Pathophysiology
Harada, M., & Nattel, S. (2021) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2020.11.002 · Cited by 126
Linz, D., Andrade, J. G., Arbelo, E., Boriani, G., BREITHARDT, G. E., Camm, A. J., Caso, V., Nielsen, J. C., Melis, M. D., Potter, T. J. R. D., et al. (2024) · EP Europace · doi:10.1093/europace/euae070 · Cited by 124
Atrial Fibrillation Therapy Now and in the Future
Woods, C. E., & Olgin, J. E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302362 · Cited by 109
Left atrial fibrosis in atrial fibrillation: Mechanisms, clinical evaluation and management
Ma, J., Chen, Q., & Ma, S. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16350 · Cited by 111
Atrial fibrillation and arterial hypertension
Kallistratos, M. S., Poulimenos, L. E., & Manolis, A. J. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.10.007 · Cited by 114
Antihypertensive treatment and risk of atrial fibrillation: a nationwide study
Marott, S. C. W., Nielsen, S. F., Benn, M., & Nordestgaard, B. G. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht507 · Cited by 107
Görenek, B., Pelliccia, A., Benjamin, E. J., Boriani, G., Crijns, H. J. G. M., Fogel, R. I., Gelder, I. C. V., Halle, M., Kudaiberdieva, G., Lane, D. A., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316676037 · Cited by 104
Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications
Lau, Y.-F., Yiu, K., Siu, C.-W., & Tse, H.-F. (2011) · Journal of Human Hypertension · doi:10.1038/jhh.2011.105 · Cited by 103
Atrial fibrillation in endurance athletes
Wilhelm, M. (2014) · European Journal of Preventive Cardiology · doi:10.1177/2047487313476414 · Cited by 95
Atrial fibrosis as a dominant factor for the development of atrial fibrillation: facts and gaps
Xintarakou, A., Tzeis, S. E., Psarras, S., Asvestas, D., & Vardas, P. E. (2020) · EP Europace · doi:10.1093/europace/euaa009 · Cited by 104
Metabolic remodelling in atrial fibrillation: manifestations, mechanisms and clinical implications
Bode, D., Pronto, J. R. D., Schiattarella, G. G., & Voigt, N. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01038-6 · Cited by 98
Karakasis, P., Theofilis, P., Vlachakis, P. K., Korantzopoulos, P. G., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010209 · Cited by 104
“…receptor antagonists may delay or prevent the onset of atrial fibrosis [103–105 , The randomized, placebo-controlled ANTIPAF-AFNET [108] trial provided further insight, demonstrating limited efficacy of angiotensin II receptor blockers in patients with AF without significant…”
Reactive oxygen species-targeted therapeutic interventions for atrial fibrillation
Sovari, A. A., & Dudley, S. C. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00311 · Cited by 82
Renin–Angiotensin System Blocking Drugs
Robles, N. R., Cerezo, I., & Hernández‐Gallego, R. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501018 · Cited by 74
2013 ESH/ESC Guidelines for the management of arterial hypertension
(2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.07.015 · Cited by 70
New developments in atrial antiarrhythmic drug therapy
Burashnikov, A., & Antzelevitch, C. N. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.245 · Cited by 64
Rothe, A. V. E., Goette, A., Kirchhof, P. F., Breithardt, G., Limbourg, T., Calvert, M., Baumert, J., & Ladwig, K. (2013) · EP Europace · doi:10.1093/europace/eut361 · Cited by 63
Thomas, M., Wu, L., & Win, K. (2014) · Journal of Biomedical Research · doi:10.7555/jbr.28.20130191 · Cited by 68
Circulating Biomarkers Predictive of Postoperative Atrial Fibrillation
Turagam, M. K., Mirza, M., Werner, P., Sra, J. S., Kress, D. C., Tajik, A. J., & Jahangir, A. (2015) · Cardiology in Review · doi:10.1097/crd.0000000000000059 · Cited by 60
Gunawardene, M., & Willems, S. (2021) · EP Europace · doi:10.1093/europace/euab257 · Cited by 56
Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis
Chaugai, S., Meng, W. Y., & Sepehry, A. A. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415619490 · Cited by 56
Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation?
Mascolo, A., Urbanek, K., Angelis, A. D., Sessa, M., Scavone, C., Berrino, L., Rosano, G. M. C., Capuano, A., & Rossi, F. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09837-7 · Cited by 56
Atrial Fibrillation and Heart Failure: Update 2015
Thihalolipavan, S., & Morin, D. P. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.07.004 · Cited by 54
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A. F., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.005 · Cited by 57
Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts
Karakasis, P., Theofilis, P., Vlachakis, P. K., Ktenopoulos, N., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093250 · Cited by 53
“While these agents modestly reduce LA volume and attenuate fibrotic remodeling in both clinical and experimental models [186], their effects appear less pronounced in populations with paroxysmal AF, likely due to minimal structural remodeling and limited RAAS activation in this setting [178].”
Schotten, U., Goette, A., & Verheule, S. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01088-w · Cited by 48
JCS / JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Journal of Arrhythmia · doi:10.1002/joa3.12714 · Cited by 41
Oxidative stress and atrial fibrillation
Pfenniger, A., Yoo, S., & Arora, R. (2024) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2024.09.011 · Cited by 49
Current Status of Catheter Ablation for Atrial Fibrillation
Inoue, K., Murakawa, Y., Nogami, A., Shoda, M., Naito, S., Kumagai, K., Miyauchi, Y., Yamane, T., Morita, N., Okumura, K., et al. (2014) · Circulation Journal · doi:10.1253/circj.cj-13-1179 · Cited by 39
The Role Of Renin Angiotensin System In Atrial Fibrillation.
Nair, G. M., Nery, P. B., Redpath, C. J., & Birnie, D. H. (2014) · PubMed Central · doi:10.4022/jafib.972 · Cited by 38
2025 Clinical practice guidelines for Atrial fibrillation and flutter
Golukhova, E. Z., Sp, G., Михайлов, Е. Н., Revishvili, A. S. H., Arakelyan, M. G., Vasilyeva, E. Y., Davtyan, K. V., Drapkina, O. M., Drozdova, L. Y., Станиславовна, К. Е., et al. (2026) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6668 · Cited by 44
Alings, M., Smit, M. D., Moes, M. L., Crijns, H. J. G. M., Tijssen, J. G. P., Brügemann, J., Hillege, H. L., Lane, D. A., Lip, G. Y. H., Smeets, J. L. R. M., et al. (2013) · Netherlands Heart Journal · doi:10.1007/s12471-013-0428-5 · Cited by 35
A New Therapeutic Framework for Atrial Fibrillation Drug Development
Ang, Y.-S., Rajamani, S., Haldar, S. M., & Hüser, J. (2020) · Circulation Research · doi:10.1161/circresaha.120.316576 · Cited by 38
Du, H., Fan, J., Ling, Z., Woo, K.-S., Su, L., Chen, S., Liu, Z., Lan, X., Zhou, B., Xu, Y., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.202309 · Cited by 37
Renin–Angiotensin System Inhibitors Prevent the Recurrence of Atrial Fibrillation
Han, M., Zhang, Y., Sun, S., Wang, Z., Wang, J., Xie, X., Gao, M., Yin, X., & Hou, Y. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182a094a1 · Cited by 32
Anti-arrhythmic strategies for atrial fibrillation
Grandi, E., & Maleckar, M. M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.012 · Cited by 32
Atrial fibrosis and substrate based characterization in atrial fibrillation: Time to move forwards
Quah, J. X., Dharmaprani, D., Tiver, K. D., Lahiri, A., Hecker, T., Perry, R., Selvanayagam, J. B., Joseph, M. X., McGavigan, A. D., & Ganesan, A. N. (2021) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.14987 · Cited by 32
Fogari, R., Zoppi, A., Maffioli, P., Mugellini, A., Preti, P. S., Perrone, T., & Derosa, G. (2012) · Clinical Cardiology · doi:10.1002/clc.21994 · Cited by 29
Prabhu, S., McLellan, A. J. A., Walters, T. E., Sharma, M., Voskoboinik, A., & Kistler, P. M. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.08.004 · Cited by 29
Wasmer, K., BREITHARDT, G. E., & Eckardt, L. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu113 · Cited by 29
Antiarrhythmic Drug Therapy for Atrial Fibrillation
Sardar, M. R., Saeed, W., & Kowey, P. R. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.017 · Cited by 28
Disertori, M., Barlera, S., Staszewsky, L. I., Latini, R., Quintarelli, S., & Franzosi, M. G. (2011) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-011-6346-0 · Cited by 28
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castellà, M., Dan, G., Dilaveris, P., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.10.022 · Cited by 34
2013 ESH/ESC GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION
Mancia, G., Fagard, R. H., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T. C., Cífková, R., Backer, G. D., Dominiczak, A. F., et al. (2014) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2014-1-7-94 · Cited by 26
Cardiometabolic Risk Factors and Atrial Fibrillation
Menezes, A. R., Lavie, C. J., DiNicolantonio, J. J., O’Keefe, J. H., Morin, D. P., Khatib, S., Messerli, F. H., & Milani, R. V. (2013) · Reviews in Cardiovascular Medicine · doi:10.3909/ricm0693 · Cited by 25
Bayés‐Genís, A., y, P. A., de Isla, L. P., Sanchís, J. M., & Heras, M. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70299-2 · Cited by 24
Clinical importance of atrial cardiomyopathy
Hammwöhner, M., Bukowska, A., Mahardika, W., & Goette, A. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.121 · Cited by 24
Marazzato, J., Blasi, F., Golino, M., Verdecchia, P., Angeli, F., & Ponti, R. D. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9040110 · Cited by 23
Pan, G., Zhou, X., & Zhao, J. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12073 · Cited by 23
Atrial Cardiomyopathy: An Unexplored Limb of Virchow's Triad for AF Stroke Prophylaxis
Darlington, A. M., & McCauley, M. D. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00011 · Cited by 24
Xu, W., Yang, Y., Zhu, J., Wu, S., Wang, J., Zhang, H., & Shao, X. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02580-2 · Cited by 22
Upstream Therapy for Atrial Fibrillation Prevention: The Role of Sacubitril/Valsartan
Vecchis, R. D., Paccone, A., & Maio, M. D. (2020) · Cardiology Research · doi:10.14740/cr1073 · Cited by 20
Autonomic Dysfunction and Neurohormonal Disorders in Atrial Fibrillation
Pfenniger, A., Geist, G. E., & Arora, R. (2021) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2020.11.012 · Cited by 19
Renin-angiotensin system inhibitors for prevention of recurrent atrial fibrillation: a meta-analysis
Li, T., Zang, W., Chen, Y.-L., Geng, N., Ma, S., & Li, X. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12063 · Cited by 18
Fakih, W., Mroueh, A., Gong, D.-S., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae101 · Cited by 17
Tsujino, Y., Sakamoto, T., Kinoshita, K., Nakatani, Y., Yamaguchi, Y., Kataoka, N., Nishida, K., & Kinugawa, K. (2019) · Heart and Vessels · doi:10.1007/s00380-019-01377-2 · Cited by 17
Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012
Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., Baumgartner, H., et al. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.11.001 · Cited by 16
Eckardt, L., Deneke, T., Diener, H., Hindricks, G., Hoffmeister, H. M., Hohnloser, S. H., Kirchhof, P. F., & Stellbrink, C. (2017) · Der Kardiologe · doi:10.1007/s12181-017-0141-5 · Cited by 16
Mohanty, S., Mohanty, P. K., Trivedi, C. G., Gianni, C., Bai, R., BURKHARDT, J. D., Gallinghouse, J. G., Horton, R., Sánchez, J., Hranitzky, P. M., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.06.007 · Cited by 15
Batra, G., Lindhagen, L., Andell, P., Erlinge, D., James, S. K., Spaak, J., & Oldgren, J. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005165 · Cited by 16
Post Cardiovascular Surgery Atrial Fibrillation. Biomarkers Determining Prognosis
Manfrini, O., Cenko, E., Ricci, B., & Bugiardini, R. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170727104930 · Cited by 15
Inhibition of the Renin-Angiotensin System for Prevention of Atrial Fibrillation
Zografos, T. A., & Katritsis, D. G. (2010) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2010.02832.x · Cited by 15
Metadata
- Authors
- Goette, A., Schön, N., Kirchhof, P., Breithardt, G., Fetsch, T., Häusler, K. G., Klein, H. U., Steinbeck, G., Wegscheider, K., & Meinertz, T.
- Affiliations
- University Hospital Münster (DE)
- Venue
- Circulation Arrhythmia and Electrophysiology
- Published
- 2012-02
- Volume
- 5
- Issue
- 1
- Pages
- 43-51
- ISSN
- 1941-3084 (ISSN-L)
- 1941-3149
- OpenAlex
- W2149897387
- Semantic Scholar
- 8bd7095a22f776dcc11d6318b6bf8f43f7fcc8f0
- Cited by
- 187
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 12 · 2023: 6 · 2022: 9 · 2021: 10 · 2020: 9 · 2019: 8 · 2018: 8 · 2017: 11 · 2016: 17 · 2015: 16 · 2014: 23 · 2013: 26 · 2012: 11
- FWCI
- 13.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Circulation Arrhythmia and Electrophysiology (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
- Keywords
- paroxysmal atrial fibrillation, angiotensin receptor blockers, olmesartan medoxomil, atrial fibrillation burden, atrial fibrillation recurrence, amiodarone, quality of life, structural heart disease, antiarrhythmic drugs, hospitalization, persistent atrial fibrillation, secondary prevention
- MeSH terms
- Atrial Fibrillation, Dose-Response Relationship, Drug, Double-Blind Method, Electrocardiography, Female, Follow-Up Studies, Germany, Humans, Imidazoles, Male, Middle Aged, Prospective Studies, Tachycardia, Paroxysmal, Tetrazoles, Time Factors, Incidence, Treatment Outcome, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
